# Parabilis Presents Zolucatetide Data at ESMO

> Parabilis Medicines to share Phase 1/2 zolucatetide results for desmoid tumor trial at Oct 24 ESMO Congress.
- Title: Parabilis Presents Zolucatetide Data at ESMO · TokenPost
- Summary: Parabilis Medicines to share Phase 1/2 zolucatetide results for desmoid tumor trial at Oct 24 ESMO Congress. Parabilis Medicines will present updated Phase…
- Keywords: parabilis medicines, zolucatetide, esmo, phase 1/2 trial, desmoid tumors, dose optimization, crypto, finance, Parabilis, Presents, Data, TokenPost
- Source: TokenPost — https://tokenpost.com/news/business/35089
- Published: 2026-10-19T22:50:44+00:00
- Read time: 1 min
- Topics: parabilis medicines, zolucatetide, esmo, phase 1/2 trial, desmoid tumors, dose optimization, crypto, finance
## Parabilis Medicines
Parabilis Medicines will present updated Phase 1/2 zolucatetide data at the European Society for Medical Oncology Congress on Oct 24.
## Dose Optimization Findings
Dose-optimization findings aim to select dosing for a planned Phase 3 desmoid tumor trial based on June 22 data cutoff.
## Presentation Details
Presentation occurs 8:45 to 10:15 a.m. ET (12:45 to 14:15 UTC) in Madrid with investor webcast at noon ET.
## Key takeaway

Parabilis Medicines will present updated Phase 1/2 zolucatetide data at the European Society for Medical Oncology Congress on Oct 24 to inform Phase 3 desmoid tumor dosing.